Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways

The discovery and clinical implementation of immune-checkpoint inhibitors (ICIs) targeting CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as recognized by the 2018 Nobel Prize for Medicine and Physiology. This groundbreaking new approach has improved the outcomes of patients with...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Nature reviews. Clinical oncology Ročník 19; číslo 1; s. 37 - 50
Hlavní autori:	Kraehenbuehl, Lukas, Weng, Chien-Huan, Eghbali, Shabnam, Wolchok, Jedd D, Merghoub, Taha
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England Nature Publishing Group 01.01.2022
Predmet:	Adenosine BTLA protein Cancer Clinical trials CTLA-4 protein Glucose metabolism Humans Immune checkpoint Immune checkpoint inhibitors Immune Checkpoint Inhibitors - pharmacology Immune Checkpoint Inhibitors - therapeutic use Immunologic Factors - metabolism Immunomodulation Immunomodulators Immunotherapy Immunotherapy - methods Lymphocytes Lymphocytes T Metabolism Neoplasms - therapy Patients PD-1 protein PD-L1 protein Receptor mechanisms Signal transduction T cell receptors Tumor necrosis factor Tumors
ISSN:	1759-4774, 1759-4782, 1759-4782
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!